Saturday 17 October 2026
Export XRTX’s income statement to Excel — free account
XORTX Therapeutics Inc.
XRTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.5% and free cash flow fell 318.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.24
0.18
−12.68%
Follow XRTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 1.09 | 0.62 | 1.99 | 28.78 | 7.21 | 4.93 | 3.53 | 2.11 |
Net Debt/EBITDA |
— | 0.80 | 1.34 | 0.12 | 5.19 | 1.02 | 0.58 | 0.62 | 0.28 |
Debt/Assets |
0.00% | 3.42% | 4.67% | 0.00% | 0.00% | 0.09% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.13 | (0.24) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.24 | 0.29 | 0.57 | 3.67 | 1.16 | 3.05 | 1.11 | 1.04 |
Capex/Depreciation |
— | 0.00 | 0.00 | (0.70) | (2.22) | (0.79) | (0.33) | (0.33) | (0.49) |
Interest Coverage |
— | (103.78) | (30.43) | (109.69) | (647.09) | 97.26 | — | — | — |
| — | (7,549.59%) | (1,316.93%) | (247.50%) | (18.45%) | (75.86%) | (37.08%) | (83.06%) | (98.00%) | |
| — | (596.89%) | (54.81%) | (75.31%) | (13.67%) | (51.53%) | (24.19%) | (69.30%) | (78.38%) | |
ROIC |
— | 0.00% | 0.00% | (80.42%) | 0.00% | 0.00% | (316.40%) | (298.29%) | (166.80%) |
Return on Tangible Assets |
— | (4,725.78%) | 126.17% | (125.70%) | (8.49%) | (81.45%) | (66.06%) | (169.62%) | (379.96%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.23 | 0.25 | 0.10 | 0.01 | 0.02 | 0.03 | 0.04 | 0.07 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (1.16) | (0.23) | (3.74) | (22.25) | (30.44) | (16.72) | (6.46) | (2.98) |
Cash per Share |
— | 1.19 | 1.01 | 0.86 | 68.75 | 35.25 | 8.70 | 4.30 | 0.91 |
Shareholders Equity per Share |
— | 0.40 | (0.27) | 6.33 | 61.04 | 23.64 | 11.71 | 5.79 | 2.20 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.40 | (0.27) | 6.33 | 61.04 | 23.64 | 11.71 | 5.79 | 2.20 |
Free Cash Flow |
— | (0.68) | (0.14) | (0.55) | (4.87) | (9.01) | (6.63) | (3.72) | (2.82) |
Working Capital |
— | 0.06 | (0.38) | 0.76 | 15.54 | 9.38 | 3.24 | 1.92 | 0.66 |
Capital Expenditures |
— | (0.03) | (0.01) | (0.01) | (0.03) | (0.05) | (0.05) | (0.04) | (0.06) |
Net Current Asset Value |
— | 0.03 | (0.38) | 0.76 | 11.87 | 5.52 | 3.24 | 1.92 | 0.66 |
| Other line items | |||||||||
Quick Ratio |
— | 1.09 | 0.62 | 0.22 | 26.97 | 6.96 | 4.25 | 3.29 | 1.58 |
Depreciation/Fixed assets |
— | 27.57 | 66.33 | 0.00 | 0.00 | 0.63 | 5.85 | 3.38 | 3.02 |
Cash ROIC |
— | (70.27%) | (28.78%) | (52.03%) | (17.15%) | (51.65%) | (81.95%) | (63.98%) | (95.76%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (1.16) | (0.23) | (3.67) | (22.11) | (30.28) | (16.61) | (6.39) | (2.92) |
Capex per Share |
— | 0.00 | 0.00 | (0.07) | (0.15) | (0.15) | (0.12) | (0.07) | (0.06) |
Average Receivables |
— | 0.02 | 0.02 | 0.03 | 0.04 | 0.06 | 0.07 | 0.04 | 0.05 |
Average Payables |
— | — | — | — | 0.67 | 1.00 | 0.86 | 0.22 | 0.35 |
Average Assets |
— | 0.47 | 0.88 | 1.27 | 9.65 | 14.98 | 8.92 | 4.78 | 3.39 |
Average Common Equity |
— | 0.04 | 0.04 | 0.39 | 7.15 | 10.18 | 5.82 | 3.99 | 2.71 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates